GlassScriptPhysician profile
Milroy J Samuel
NPI 1982647566
$17,443.21
in general payments reported to CMS, 2019-2025
48 companies · $869 in 2025
The $869 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $570 · 2021: $8,904 · 2022: $3,606 · 2023: $1,841 · 2024: $965 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,674.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $10,902.85 | 2021-2022 | |
| Uswm, LLC | $718.73 | 2021-2023 | Lucemyra, Zimhi |
| Tris Pharma INC | $551.52 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $515.56 | 2021-2025 | Vraylar |
| Minerva Surgical, INC | $477.13 | 2019-2023 | |
| Indivior INC. | $443.16 | 2019-2025 | Sublocade |
| Axsome Therapeutics, INC. | $441.25 | 2022-2025 | Auvelity |
| Corcept Therapeutics | $323.24 | 2024-2025 | Korlym |
| Currax Pharmaceuticals LLC | $320.75 | 2019-2024 | Contrave, Onzetra Xsail |
| Teva Pharmaceuticals USA, INC. | $314.88 | 2021-2023 | Austedo Xr, Austedo |
| Braeburn INC. | $265.64 | 2023-2025 | Brixadi |
| Alkermes, INC. | $232.53 | 2021-2025 | Lybalvi |
| Lupin INC. | $227.53 | 2019-2021 | |
| Orexo US, INC. | $215.04 | 2019-2024 | Zubsolv |
| Redhill Biopharma INC. | $196.68 | 2021 |
Show all 41 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milroy Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.